Description: Aravive, Inc., a clinical stage biotechnology company, focuses on developing therapies for solid tumors and hematologic malignancies. It is developing AVB-S6-500, a GAS6 binding protein and AXL decoy receptor, for the treatment of ovarian cancer, as well as for renal cell carcinoma, acute myeloid leukemia, triple negative breast cancer and pancreatic cancer. The company was formerly known as Versartis, Inc. and changed its name to Aravive, Inc. in October 2018. Aravive, Inc. is based in Houston, Texas.
Home Page: aravive.com
ARAV Technical Analysis
River Oaks Tower
Houston,
TX
77098
United States
Phone:
936 355 1910
Officers
| Name | Title |
|---|---|
| Dr. Fredric N. Eshelman Pharm.D. | Exec. Chairman |
| Dr. Gail F. McIntyre CH (ASCP), DABT, Ph.D. | Pres, CEO & Director |
| Dr. Jeffrey L. Cleland Ph.D. | Co-Founder |
| Dr. Joshua Silverman Ph.D. | Co-Founder |
| Mr. Rudy C. Howard B.A., CPA, CPA | Chief Financial Officer |
| Dr. Leonard Scott Dove Ph.D. | Chief Operating Officer |
| Mr. Marek Ciszewski J.D. | VP of Investor Relations |
| Dr. Randy L. Anderson | Sr. VP of Data Sciences |
| Dr. Robert B. Geller M.D. | Chief Medical Officer |
| Kenneth L. Guernsey | Sec. |
Exchange: NASDAQ
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 7.2785 |
| Price-to-Sales TTM: | 11.4147 |
| IPO Date: | 2014-03-21 |
| Fiscal Year End: | December |
| Full Time Employees: | 23 |